ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,221.42
-0.02%
US Tech 100
17,714.00
0.18%
Dow Jones
39,431.51
-0.21%
Brent Oil
83.21
1.00%
Bitcoin
63,097.45
2.68%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Immutep Ltd (IMMP) Quote

Immutep Ltd

Immutep Ltd (IMMP)

NASDAQ
2.93
0.05
(1.74%)
At close: May 13 4:00PM
Delayed by 15 minutes
2.93
0.05
( 1.74% )
After Hours: 4:25PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
2.93
Bid
2.87
Ask
3.02
Volume
210,586
2.87 Day's Range 3.06
0.00 52 Week Range 0.00
Market Cap
534.288M
Previous Close
2.88
Open
2.88
Last Trade
1
@
2.97
Last Trade Time
16:37:21
Financial Volume
$ 616,556
VWAP
2.9278
Average Volume (3m)
-
Shares Outstanding
1,187,306,000
Dividend Yield
-
PE Ratio
-13.39
Earnings Per Share (EPS)
-0.03
Revenue
-
Net Profit
-39.9M

About Immutep Ltd

Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesse... Immutep Ltd. is a clinical stage biotechnology company developing novel LAG-3 immunotherapy for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3's unique ability to stimulate or suppress the immune response. Immutep's lead clinical candidate, eftilagimod alpha ('efti'), is a soluble LAG-3 protein and first-in-class MHC Class II agonist that stimulates both innate and adaptive immunity to fight cancer. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
www.immutep.com
Headquarters
Sydney, New South Wales, Aus
Founded
1970
Immutep Ltd is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker IMMP. The last closing price for Immutep was $2.88. Over the last year, Immutep shares have traded in a share price range of $ 0.00 to $ 0.00.

Immutep currently has 1,187,306,000 shares outstanding. The market capitalization of Immutep is $534.29 million. Immutep has a price to earnings ratio (PE ratio) of -13.39.

Immutep (IMMP) Options Flow Summary

IMMP Options Flow

Overall Flow

Bullish

Net Premium

159k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

IMMP Latest News

More News

Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trialFour of six...

May 02 2024
GlobeNewswire Inc.

Immutep Quarterly Activities Report Q3 FY24

Media Release First clinical data from the safety lead-in of AIPAC-003 in metastatic breast cancer shows 90mg dosing of efti safe and well tolerated: 50% overall response rate, including one...

April 29 2024
GlobeNewswire Inc.

Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

Media Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows a preliminary 26.9...

April 24 2024
GlobeNewswire Inc.

Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761

Media Release Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to restore balance to the immune system and...

April 18 2024
GlobeNewswire Inc.

Immutep Receives Positive Feedback from the Spanish Medicines Agency for Upcoming TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

SYDNEY, AUSTRALIA, April 17, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3...

April 17 2024
GlobeNewswire Inc.

Immutep Announces First Clinical Data from 90mg Dosing of Efti

Data from the safety lead-in of the AIPAC-003 trial shows 90mg efti in combination with paclitaxel is safe and well toleratedEncouraging initial efficacy in six metastatic breast cancer patients...

March 05 2024
GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

January 30 2024
Edgar (US Regulatory)

Immutep Quarterly Activities Report Q2 FY24

Media Release Excellent clinical data reported from TACTI-002 Phase II trial, including median Overall Survival of 35.5 months in first line non-small cell lung cancer (1L NSCLC) patients...

January 30 2024
GlobeNewswire Inc.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HROWHarrow Inc
$ 13.90
(15.16%)
49.37k
HYZNHyzon Motors Inc
$ 0.6168
(14.18%)
277.48k
TCJHTop KingWin Ltd
$ 0.5349
(14.03%)
49.41k
VXRTVaxart Inc
$ 0.93
(13.41%)
341.58k
AIHAesthetic Medical International Holdings Group Ltd
$ 0.5294
(12.64%)
610
AUGXAugmedix Inc
$ 1.53
(-34.62%)
107.18k
AKYAAkoya BioSciences Inc
$ 2.97
(-27.91%)
30.48k
SHIMShimmick Corporation
$ 3.00
(-17.58%)
10.63k
TMCTMC the Metals Company Inc
$ 1.34
(-11.84%)
261.24k
INMInMed Pharmaceuticals Inc
$ 0.2501
(-10.65%)
19k
BIOLBiolase Inc
$ 0.1762
(-2.60%)
5.24M
LIFEaTyr Pharma Inc
$ 1.75
(2.94%)
4.5M
FFIEFaraday Future Intelligent Electric Inc
$ 0.0649
(6.39%)
3.37M
SQQQProShares UltraPro Short QQQ
$ 10.56
(0.09%)
2M
TRIPTripAdvisor Inc
$ 18.55
(-0.48%)
1.97M

IMMP Discussion

View Posts
Monksdream Monksdream 1 week ago
IMMP under $3
👍️0
Monksdream Monksdream 7 months ago
IMMP under $2
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
The Night Stalker The Night Stalker 11 months ago
strong
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
The Night Stalker The Night Stalker 11 months ago
ready
👍️0
The Night Stalker The Night Stalker 11 months ago
nice
👍️0
The Night Stalker The Night Stalker 11 months ago
strong
👍️0
The Night Stalker The Night Stalker 12 months ago
watching
👍️0
The Night Stalker The Night Stalker 12 months ago
watching
👍️0
The Night Stalker The Night Stalker 12 months ago
dip
👍️0
The Night Stalker The Night Stalker 12 months ago
dip
👍️0
The Night Stalker The Night Stalker 12 months ago
nice
👍️0
The Night Stalker The Night Stalker 12 months ago
im in my bio DRMA, one at a time


RIGL rip for more
👍️0
The Night Stalker The Night Stalker 12 months ago
beast
👍️0
DewDiligence DewDiligence 12 months ago
IMMP +65% on interim (single-arm) phase-2 data for LAG-3 drug with Keytruda in NSCLC:

https://finance.yahoo.com/news/immutep-efti-combination-pembrolizumab-achieves-120000596.html

IMMP’s eftilagimod alpha is a LAG-3 protein that targets the same biologic pathway as BMY’s relatlimab, one of the component drugs (along with Opdivo) in Opdulag.

BMY’s Opdulag, which was FDA approved in Mar 2022 for first-line melanoma, is already selling at an annualized rate of $500M in the US alone (#msg-171784010).

Please see #msg-168259768 for related info.
👍️0
Invest-in-America Invest-in-America 12 months ago
IMMP: Very likely the hands-down WINNER of this Wall Street day, Peeps!!! (Just when ya thought that CANCER was no longer TRENDING.)

👍️0
stocks2watch stocks2watch 2 years ago
Going to move up
👍️0
make it happen make it happen 3 years ago
It's cool covered most average was $3.68
👍️0
calahan67 calahan67 3 years ago
I think you're not taking into account whats in the pipeline mainly several studies involving much larger pharmaceutical interested the immune boosting properties of eftaligamod. Imo this company and ceo are the real deal. Forget the outlays and remember its research and development that costs the most up front no matter what pharm you're talking about
👍️0
make it happen make it happen 3 years ago
More debt than revenue, large negatives on everything (cash flow, returns and profit margins.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 6.35M
Revenue Per Share (ttm) 0.14
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -17.07M
Net Income Avi to Common (ttm) -27.36M
Diluted EPS (ttm) -0.4500

Total Debt (mrq) 9.75M
Book Value Per Share (mrq) 0.94

Cash Flow Statement
Operating Cash Flow (ttm) -14.67M
Levered Free Cash Flow (ttm) -7.67M
👍️0
sgunderbarth sgunderbarth 3 years ago
IMMP Interesting action....
👍️0
ClayTrader ClayTrader 3 years ago
* * $IMMP Video Chart 04-08-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
make it happen make it happen 3 years ago
Any positives in the numbers? Decent news but will need to raise money to keep anything going imho

IMMP is "ELIGIBLE" to receive development based milestones and sales based royalties. They do not have sales and drug is not out.


Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65 will blow through it and need a serious capital raise imho
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 3 years ago
Had R/S a couple years ago and was $0.53 about a year ago
👍️0
make it happen make it happen 3 years ago
Quarterly growth -76.9%, returns are negative, zero profit and cash flow is very negative.

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -300.79%

Management Effectiveness
Return on Assets (ttm) -20.00%
Return on Equity (ttm) -61.68%

Income Statement
Revenue (ttm) 4.85M
Revenue Per Share (ttm) 0.11
Quarterly Revenue Growth (yoy) -76.90%
Gross Profit (ttm) -6.66M
EBITDA -13.03M
Net Income Avi to Common (ttm) -20.89M
Diluted EPS (ttm) -0.4600

Balance Sheet
Total Cash Per Share (mrq) 0.65
Total Debt (mrq) 7.45M
Book Value Per Share (mrq) 0.71

Cash Flow Statement
Operating Cash Flow (ttm) -11.2M
Levered Free Cash Flow (ttm) -5.86M
👍️0
make it happen make it happen 3 years ago
I agree it states that Novartis is in chagre and IMMP is "ELIGIBLE" to receive milestones and payments. Previous reverse split. IMHO prob going to be bled
👍️0
reverse_long reverse_long 3 years ago
IMMP never holds any spikes. Every time it has fastrack or patent news it dumps away. It is the real deal to dump very hard. GLTA!
👍️0
calahan67 calahan67 3 years ago
This is the real deal folks
👍️0
ClayTrader ClayTrader 3 years ago
* * $IMMP Video Chart 03-25-2021 * *

Link to Video - click here to watch the technical chart video

👍️0
DewDiligence DewDiligence 3 years ago
IMMP up on BMY's LAG-3 coattails: #msg-162784750.
👍️0
calahan67 calahan67 3 years ago
And they have a very sharp ceo if you've seen any of their videos he tells it straight up imo
👍️0
calahan67 calahan67 3 years ago
Up huge on no news a great big sleeper imo
👍️0
calahan67 calahan67 3 years ago
Looks like accumulation is beginning a slow churn higher
👍️0
everything everything 3 years ago
Interesting company, looks to be in reversal but dip opportunity may be in the works.
👍️0
akamaii akamaii 3 years ago
Like it here
👍️0
lecorb lecorb 3 years ago
$IMMP: TIPRANKS, SCORE, UPGRADE TO 10 OUTPERFORM! ANALIST RATINGS: PT: $6.50 MODERATE BUY! LOW: @5.50, MED:@6.50, HI: $8.00 Jason McCarthy Maxim Group 5 Stars target $8.00 ranking Buy analystAction Reiterated date 6 days ago Last calification.
👍️0

Your Recent History

NASDAQ
IMMP
Immutep
BIT
UC0HT3
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved